“Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s612. Accessed April 19, 2026. https://skin.dermsquared.com/skin/article/view/3814.